Six years of peer experience and extraordinary journey: Kemena's 6th anniversary Academic Summit held in Guangzhou

Source: on November 5, 2017, domestic well-known experts of Beida Pharmaceutical Co., Ltd witnessed the 19th National Congress of the Communist Party of China shortly after the opening ceremony of Kemena's 6th anniversary celebration, and made important arrangements for the implementation of innovation driven development strategy and healthy China strategy Following the spring breeze of China's pharmaceutical innovation, the first prize of national science and technology progress won the project and the sixth anniversary Academic Summit of Kemena's listing, a major special scientific and technological achievement of national major new drug development project during the 11th and 12th Five Year Plan, was held in Guangzhou on November 4 Nearly 600 experts and scholars from the field of lung cancer gathered in Yangcheng, focusing on major topics of tumor treatment, talking about the new development direction of lung cancer treatment, and through group discussion in multiple sub venues, combined with in-depth analysis of cases in clinical practice, to solve the problems of diagnosis and treatment encountered in clinical practice, and to share and exchange treatment experience Speech by academician sang Guowei, academician Sun Yan and academician Yu Jinming was jointly organized by China pharmaceutical promotion association and Beida pharmaceutical industry Academician sang Guowei, academician Sun Yan and academician Yu Jinming congratulated on the opening of the conference in the form of video speeches, and placed high hopes on the innovation and development of Beida pharmaceutical industry Professor Guan Zhongzhen, Professor Liao Meilin, Professor Wu Yilong, Professor Shi Yuankai, Professor Zhi Xiuyi, Professor Wang afforest, Professor Wang Changli, Professor Feng Jifeng, Professor Li Yin, Professor Luo Rongcheng, Professor Zhang Lanjun and other 11 renowned authoritative experts in the field of tumor took the chair The meeting was presided over by song Ruilin, executive chairman of China pharmaceutical promotion association, and attended by senior executives such as Dr Ding liming, chairman and CEO of Beida pharmaceutical President Song Ruilin presided over the conference In warm applause, Dr Ding Liming delivered a welcome speech on behalf of the organizer He first extended a warm welcome to the leaders and guests who came to witness the 6th anniversary of Kemena's listing, and sincerely thanked the leaders at all levels and the experts for their concern and support for Beida pharmaceutical industry In his welcome speech, Dr Ding Liming recalled that Kemena has gone through six years step by step Dr Ding Liming said with deep feeling that although Kemena is only six years old, she has grown into a "strong young man" and created very good social and economic benefits In 2016, Kemena's sales exceeded the 1 billion mark By the third quarter of this year, the cumulative sales had exceeded 4.2 billion yuan, benefiting nearly 150000 patients and becoming the industry leader In total, 422 papers and 138 SCI papers were published, with an impact factor of more than 400 points Kemena's follow-up free drug use project, jointly carried out with the China Association for the promotion of drugs, has donated 2.6 million boxes of drugs to nearly 50000 patients, with a market value of more than 6 billion yuan, highly recognized and widely praised by the Party committee, the government and the community Glory is never a man's merit Kemena's success is the work and dedication of many experts and scholars Dr Ding Liming said affectionately in his speech that since the research and development of Kemena, many experts led by academician Sun Yan, the international leader of Clinical Oncology, have participated in the clinical research in person, and Professor Wu Yilong and Professor Shi Yuankai have led the exploration of Kemena's new indications, which has attracted wide attention of the international oncology community and made Kemena shine on the world stage Dr Ding also thanked the party committees at all levels, the government and the major science and technology projects of the national major new drug creation project for their strong support, which helped Beida solve many difficulties in the development process Dr Ding liming was very excited when experts from the academic feast gathered to talk about this year's gratifying achievements At present, the company has more than 20 new drug projects under research, of which 7 projects have entered the clinical stage and 3 projects have entered the clinical stage III It is particularly worth mentioning that the company's developing ensortinib (x-396), on the basis of being approved for phase I, II and III clinical trials in 2016, was approved to enter the international multi center phase III clinical research this year If Kemena is the first small molecule targeted anticancer drug independently researched and developed in China, ensartinib is expected to become the first global target drug to be launched synchronously led by Chinese companies Looking back on the achievements, I feel inspired and confident in looking forward to the future After the 19th National Congress of the Communist Party of China, the innovation of Chinese medicine has ushered in a new spring Dr Ding Liming said that the clarion call for a new era has been sounded, and Beida will seize the opportunity, take advantage of the situation and forge ahead We also look forward to your leaders and experts' encouragement and support as always, and work together with Beida Beidading will not be disappointed We will roll up our sleeves and work hard to develop more new and good medicines for the people and make greater contributions to the development of Chinese medicine In their speeches, Professor Guan Zhongzhen and Professor Liao Meilin said that they are very happy to witness Kemena's brilliant history From the grand listing of Kemena in the Great Hall of the people in Beijing in 2011 to today's sixth anniversary, many patients have benefited from Kemena, extending their lives and improving their quality of life The listing of Kemena is a landmark event in the field of cancer treatment in China He hoped that Beida would develop more innovative and good drugs like Kemena as soon as possible to help China's cancer treatment level step into a new stage Professor Liao Meilin combined with his 60 years of experience in medicine, from the past dependence on imported drugs to the gradual emergence of domestic innovative drugs, and now the steady improvement of innovative drugs, more and more Chinese people use domestic innovative drugs Among them, the most pleased thing for her is the success of Kemena It enables Chinese lung cancer patients to use targeted drugs with high quality, low price and good efficacy, which is of great significance and a milestone in the field of cancer treatment in China With the applause of expectation and encouragement, 26 domestic authoritative experts and company executives stepped onto the stage to jointly open the launch ceremony of Kemena's 6th anniversary celebration under the witness of all participants Famous professors in oncology share academic research In the academic exchange, Professor Shi Yuankai shared the real world data of exetane, Professor Fan Yun shared the treatment strategy of EGFR mutated brain metastasis NSCLC, Professor Lin Dongmei shared the development and application of detection technology in the era of precision treatment, Professor Zhang Bin shared my opinion on the clinical application of the second generation sequencing, Professor Lu Shun shared the new progress of lung cancer immunotherapy, Professor Liu Xiaoqing Enjoy the academic research on whether the era of EGFR-TKI postoperative adjuvant therapy has come Dr Tan Feilai and Dr Liang Congxin introduced the products of Beida entering phase III clinical Prof Zhang Shucai, Prof Shi Meiqi, Prof Yang Jinji, Prof Huang Cheng, Prof Lu Shun, Prof Luo Rongcheng, Prof Liu Xiaoqing, Prof fan Yun, Prof Yang Yue, Prof Zhang Lanjun and other experts took part in the activity link of "big idea", and expressed their opinions around the issues that everyone concerned On behalf of the company, Dr Tan Feilai and Dr Liang Congxin introduced the follow-up products of Beida entering into phase III clinical oncology field Professor Wu Yilong summarizes the morning meeting In the afternoon, the conference was divided into five sub sessions, i.e oncology department, respiratory department, thoracic surgery, multi-disciplinary, middle-aged and young people In-depth discussions and exchanges were held around various fields Professor Wu Yilong summed up the sharing, thinking collision and academic exchange of the big coffee at the conference The experts and scholars attending the conference expressed that the conference was of great significance and fruitful results We also hope that Beida will continue to innovate and surpass, and make more brilliant achievements to add luster to the revitalization of national pharmaceutical industry Group photo of executives attending the meeting